In a filing, Atyr Pharma Inc revealed its Director SCHIMMEL PAUL acquired Company’s shares for reported $0.1 million on Jul 24 ’24. In the deal valued at $1.93 per share,52,300 shares were bought. As a result of this transaction, SCHIMMEL PAUL now holds 413,023 shares worth roughly $1.23 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SCHIMMEL PAUL bought 41,052 shares, generating $71,500 in total proceeds. Upon buying the shares at $1.74, the Director now owns 354,075 shares.
Before that, SCHIMMEL PAUL bought 6,648 shares. Atyr Pharma Inc shares valued at $12,075 were divested by the Director at a price of $1.82 per share. As a result of the transaction, SCHIMMEL PAUL now holds 360,723 shares, worth roughly $1.08 million.
Wells Fargo initiated its Atyr Pharma Inc [ATYR] rating to an Overweight in a research note published on October 04, 2024; the price target was $17. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Oppenheimer also remained covering ATYR and has decreased its forecast on July 05, 2023 with a “Perform” recommendation from previously “an Outperform” rating. RBC Capital Mkts started covering the stock on October 12, 2021. It rated ATYR as “an Outperform”.
Price Performance Review of ATYR
On Friday, Atyr Pharma Inc [NASDAQ:ATYR] saw its stock jump 12.83% to $2.99. Over the last five days, the stock has gained 34.08%. Atyr Pharma Inc shares have risen nearly 112.06% since the year began. Nevertheless, the stocks have risen 124.81% over the past one year. While a 52-week high of $2.86 was reached on 10/18/24, a 52-week low of $1.08 was recorded on 01/02/24. SMA at 50 days reached $1.94, while 200 days put it at $1.80.
Levels Of Support And Resistance For ATYR Stock
The 24-hour chart illustrates a support level at 2.74, which if violated will result in even more drops to 2.49. On the upside, there is a resistance level at 3.13. A further resistance level may holdings at 3.28. The Relative Strength Index (RSI) on the 14-day chart is 83.61, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.59, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 2.61%. Stochastics %K at 89.33% indicates the stock is a selling.
How much short interest is there in Atyr Pharma Inc?
A steep rise in short interest was recorded in Atyr Pharma Inc stocks on 2024-09-30, growing by 0.92 million shares to a total of 1.36 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 0.44 million shares. There was a rise of 67.7%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 21, 2021 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $19 price target.
